Iksuda Therapeutics
Iksuda Therapeutics develops Antibody Drug Conjugates (ADCs) targeting difficult-to-treat cancers, including those that are resistant to current therapies. The Company is building a pipeline of best in class therapies which are carefully customised for each tumour type.
In addition to Iksuda’s own pipeline of best-in-class products, the Company is actively collaborating with global leaders in the field through licensing deals.
Iksuda’s focus is on providing more effective treatments for patients with limited treatment options, and its products target conditions such as diffuse B-cell lymphoma, breast cancer, lung cancer, gynaecological tumours – such as those of the ovary and cervix – pancreatic, and colorectal cancer.
Iksuda is working with leading research institutions in the US and Europe to develop exciting new therapies for the future. The company is flexible in its approach to collaboration and welcomes discussions with other commercial and academic research teams.
The Company is based at the Biosphere in central Newcastle and also maintains an office in Boston, Massachusetts. The Company employs a team of fourteen highly skilled staff as well as specialist consultants.
